Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication

Tetsuya Mitsudomi, Tsunehiro Oyama, Kinue Nishida, Akira Ogami, Toshihiro Osaki, Kenji Sugio, Kosei Yasumoto, Keizo Sugimachi, Adi F. Gazdar

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

We examined 110 patients with non-small cell lung cancer who underwent consecutive pulmonary resection for loss of heterozygosity (LOH) at the short arm of chromosome 3 (3p). We performed a PCR-based microsatellite polymorphism analysis for detection of LOH. The microsatellite markers used were D3S966 (3p21.3), D3S1007 (3p21.3-22), and D3S1228 (3p14.1-14.3). Of 98 informative cases, 3p LOH was found in 45 (46%), 3p LOH was more prevalent in squamous cell carcinoma (24/35, 69%) than in adenocarcinoma (18/52, 35%; P = 0.0019). There was no significant association between 3p LOH and sex, disease stage, or grade of differentiation. However, patients with 3p LOH tended to survive for a shorter period of time (P = 0.0631, log rank test). There was no such tendency in squamous cell carcinoma (P = 0.7513), but in adenocarcinoma, the difference of survival was significant (P = 0.0015). Cox's proportional hazards model also predicted that 3p LOH was an independent poor prognostic msrker in adenocarcinoma (P = 0.0502) but not in squamous cell carcinoma or in the entire cohort (P = 0.7866 and 0.1371, respectively). LOH at 3p may help to identify non-small cell lung cancer patients with a poor prognosis, who thus need an intensive postoperative follow-up protocol or who are suitable for novel investigational therapeutic approaches. It is also suggested that the putative tumor suppressor gene at 3p may have a different role in squamous cell carcinoma and adenocarcinoma of the lung.

Original languageEnglish (US)
Pages (from-to)1185-1189
Number of pages5
JournalClinical Cancer Research
Volume2
Issue number7
StatePublished - Jul 1996

Fingerprint

Loss of Heterozygosity
Non-Small Cell Lung Carcinoma
Squamous Cell Carcinoma
Adenocarcinoma
Microsatellite Repeats
Chromosomes, Human, Pair 3
Tumor Suppressor Genes
Proportional Hazards Models
Polymerase Chain Reaction
Lung
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mitsudomi, T., Oyama, T., Nishida, K., Ogami, A., Osaki, T., Sugio, K., ... Gazdar, A. F. (1996). Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clinical Cancer Research, 2(7), 1185-1189.

Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. / Mitsudomi, Tetsuya; Oyama, Tsunehiro; Nishida, Kinue; Ogami, Akira; Osaki, Toshihiro; Sugio, Kenji; Yasumoto, Kosei; Sugimachi, Keizo; Gazdar, Adi F.

In: Clinical Cancer Research, Vol. 2, No. 7, 07.1996, p. 1185-1189.

Research output: Contribution to journalArticle

Mitsudomi, T, Oyama, T, Nishida, K, Ogami, A, Osaki, T, Sugio, K, Yasumoto, K, Sugimachi, K & Gazdar, AF 1996, 'Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication', Clinical Cancer Research, vol. 2, no. 7, pp. 1185-1189.
Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Sugio K et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clinical Cancer Research. 1996 Jul;2(7):1185-1189.
Mitsudomi, Tetsuya ; Oyama, Tsunehiro ; Nishida, Kinue ; Ogami, Akira ; Osaki, Toshihiro ; Sugio, Kenji ; Yasumoto, Kosei ; Sugimachi, Keizo ; Gazdar, Adi F. / Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. In: Clinical Cancer Research. 1996 ; Vol. 2, No. 7. pp. 1185-1189.
@article{a9fc9d986f46427fb12133e758a7f5f1,
title = "Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication",
abstract = "We examined 110 patients with non-small cell lung cancer who underwent consecutive pulmonary resection for loss of heterozygosity (LOH) at the short arm of chromosome 3 (3p). We performed a PCR-based microsatellite polymorphism analysis for detection of LOH. The microsatellite markers used were D3S966 (3p21.3), D3S1007 (3p21.3-22), and D3S1228 (3p14.1-14.3). Of 98 informative cases, 3p LOH was found in 45 (46{\%}), 3p LOH was more prevalent in squamous cell carcinoma (24/35, 69{\%}) than in adenocarcinoma (18/52, 35{\%}; P = 0.0019). There was no significant association between 3p LOH and sex, disease stage, or grade of differentiation. However, patients with 3p LOH tended to survive for a shorter period of time (P = 0.0631, log rank test). There was no such tendency in squamous cell carcinoma (P = 0.7513), but in adenocarcinoma, the difference of survival was significant (P = 0.0015). Cox's proportional hazards model also predicted that 3p LOH was an independent poor prognostic msrker in adenocarcinoma (P = 0.0502) but not in squamous cell carcinoma or in the entire cohort (P = 0.7866 and 0.1371, respectively). LOH at 3p may help to identify non-small cell lung cancer patients with a poor prognosis, who thus need an intensive postoperative follow-up protocol or who are suitable for novel investigational therapeutic approaches. It is also suggested that the putative tumor suppressor gene at 3p may have a different role in squamous cell carcinoma and adenocarcinoma of the lung.",
author = "Tetsuya Mitsudomi and Tsunehiro Oyama and Kinue Nishida and Akira Ogami and Toshihiro Osaki and Kenji Sugio and Kosei Yasumoto and Keizo Sugimachi and Gazdar, {Adi F.}",
year = "1996",
month = "7",
language = "English (US)",
volume = "2",
pages = "1185--1189",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication

AU - Mitsudomi, Tetsuya

AU - Oyama, Tsunehiro

AU - Nishida, Kinue

AU - Ogami, Akira

AU - Osaki, Toshihiro

AU - Sugio, Kenji

AU - Yasumoto, Kosei

AU - Sugimachi, Keizo

AU - Gazdar, Adi F.

PY - 1996/7

Y1 - 1996/7

N2 - We examined 110 patients with non-small cell lung cancer who underwent consecutive pulmonary resection for loss of heterozygosity (LOH) at the short arm of chromosome 3 (3p). We performed a PCR-based microsatellite polymorphism analysis for detection of LOH. The microsatellite markers used were D3S966 (3p21.3), D3S1007 (3p21.3-22), and D3S1228 (3p14.1-14.3). Of 98 informative cases, 3p LOH was found in 45 (46%), 3p LOH was more prevalent in squamous cell carcinoma (24/35, 69%) than in adenocarcinoma (18/52, 35%; P = 0.0019). There was no significant association between 3p LOH and sex, disease stage, or grade of differentiation. However, patients with 3p LOH tended to survive for a shorter period of time (P = 0.0631, log rank test). There was no such tendency in squamous cell carcinoma (P = 0.7513), but in adenocarcinoma, the difference of survival was significant (P = 0.0015). Cox's proportional hazards model also predicted that 3p LOH was an independent poor prognostic msrker in adenocarcinoma (P = 0.0502) but not in squamous cell carcinoma or in the entire cohort (P = 0.7866 and 0.1371, respectively). LOH at 3p may help to identify non-small cell lung cancer patients with a poor prognosis, who thus need an intensive postoperative follow-up protocol or who are suitable for novel investigational therapeutic approaches. It is also suggested that the putative tumor suppressor gene at 3p may have a different role in squamous cell carcinoma and adenocarcinoma of the lung.

AB - We examined 110 patients with non-small cell lung cancer who underwent consecutive pulmonary resection for loss of heterozygosity (LOH) at the short arm of chromosome 3 (3p). We performed a PCR-based microsatellite polymorphism analysis for detection of LOH. The microsatellite markers used were D3S966 (3p21.3), D3S1007 (3p21.3-22), and D3S1228 (3p14.1-14.3). Of 98 informative cases, 3p LOH was found in 45 (46%), 3p LOH was more prevalent in squamous cell carcinoma (24/35, 69%) than in adenocarcinoma (18/52, 35%; P = 0.0019). There was no significant association between 3p LOH and sex, disease stage, or grade of differentiation. However, patients with 3p LOH tended to survive for a shorter period of time (P = 0.0631, log rank test). There was no such tendency in squamous cell carcinoma (P = 0.7513), but in adenocarcinoma, the difference of survival was significant (P = 0.0015). Cox's proportional hazards model also predicted that 3p LOH was an independent poor prognostic msrker in adenocarcinoma (P = 0.0502) but not in squamous cell carcinoma or in the entire cohort (P = 0.7866 and 0.1371, respectively). LOH at 3p may help to identify non-small cell lung cancer patients with a poor prognosis, who thus need an intensive postoperative follow-up protocol or who are suitable for novel investigational therapeutic approaches. It is also suggested that the putative tumor suppressor gene at 3p may have a different role in squamous cell carcinoma and adenocarcinoma of the lung.

UR - http://www.scopus.com/inward/record.url?scp=0029889028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029889028&partnerID=8YFLogxK

M3 - Article

C2 - 9816286

AN - SCOPUS:0029889028

VL - 2

SP - 1185

EP - 1189

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -